Tryptamine Therapeutics Limited
TYPTF
$0.015
$0.000.00%
| 12/31/2024 | 02/29/2024 | 11/30/2023 | 11/30/2023 | 08/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.75% | -7.55% | 32.97% | 32.97% | -162.40% |
| Total Depreciation and Amortization | -2.94% | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.74% | -323.61% | -49.74% | -49.74% | 1,240.60% |
| Change in Net Operating Assets | -- | 202.46% | -109.73% | -109.73% | 433.51% |
| Cash from Operations | 2.75% | -75.12% | 15.46% | 15.46% | -53.31% |
| Capital Expenditure | 2.72% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | 2.72% | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -99.17% | 1,356.74% | 1,356.74% | -90.67% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -- | -- | -- | -- |
| Cash from Financing | -2.75% | -99.25% | 1,321.83% | 1,321.83% | -90.50% |
| Foreign Exchange rate Adjustments | -2.74% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.75% | -198.87% | 277.17% | 277.17% | -178.63% |
